The androgenic agent also has an anabolic effect. In target cells (skin, prostate, seminal vesicles, epididymus), 5-alpha-reductase is reduced to 5-alpha-dihydrotestosterone, which specifically interacts with receptors on the cell surface and penetrates into the nucleus. In some tissues (including the hypothalamus) turns into estradiol.
In men, it stimulates the development and activity of the gonads of the prostate gland, seminal vesicles, the formation of secondary male characteristics (growth of a low voice, the growth of a beard and mustache) increases libido and potency; indirectly, through the central nervous system, it affects sexual behavior.
Reduces the deposition of fat and the excretion of trace elements.
It inhibits the production and release of luteinizing hormone and follicle-stimulating hormone by the pituitary gland.
It has anabolic effects: it participates in the growth of the skeleton increases the mass of skeletal muscles; it causes the retention of nitrogen phosphorus and potassium sulfur ions necessary for protein synthesis.
- Absorption: the maximum concentration after intramuscular administration of the drug is observed after 25-5 hours.
- Distribution: in the blood, testosterone binds (about 98%) to a specific fraction of globulins that bind testosterone and estradiol.
- Metabolism: Testosterone is mainly metabolized in the liver to form low-level androsterone and inactive etiocholanolone.
- Excretion: excreted as metabolites mainly by the kidneys and through the intestine (about 6%). The half-life is 3-4 hours.
In men: replacement therapy for primary and secondary hypogonadism (delayed puberty hypopituitarism eunuchoidism post-castration syndrome oligospermia).
In women: progressive inoperable metastatic breast cancer.
Hypersensitivity to testosterone or any other component of the drug;
- prostate cancer;
- breast cancer;
- nephrotic stage of chronic glomerulonephritis;
- prostatic hypertrophy with urinary retention;
- liver / kidney failure;
- chronic heart failure;
- diabetes mellitus;
- a history of myocardial infarction;
- common atherosclerosis.
- Asthenic physique;
- older age in men;
- in men with arterial hypertension;
- in patients with epilepsy;
- in patients with migraine;
- in patients with coronary heart disease prone to edema;
- adolescence in boys (before puberty);
- benign prostatic hyperplasia.